BioCentury
PODCAST | Product Development

‘A science problem we can solve:’ a BioCentury podcast

GSK’s Barron, Vir’s Scangos on the science behind COVID-19 and the partnerships seeking to defeat it

May 29, 2020 2:07 AM UTC

The scientific progress toward finding countermeasures against COVID-19 in the past five months is “unprecedented in the history of the world,” GSK’s Hal Barron said on the latest BioCentury This Week - Special Report podcast.

Barron, CSO and president of R&D at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), joined BioCentury Editor in Chief Simone Fishburn and George Scangos, president and CEO of Vir Biotechnology Inc. (NASDAQ:VIR), in a wide-ranging discussion exploring the science of the novel coronavirus and the lessons from Ebola. Barron and Scangos also provided insider insights into the industry collaborations that have quickly assembled to share ideas, compounds and other resources to develop vaccines and therapies for COVID-19...

BCIQ Company Profiles

GSK plc

Vir Biotechnology Inc.